#USA #oncology #Rochester #URMC #Indivumed

Strengthening Patient-Centered Cancer Research

In an exciting development in oncology research, Indivumed has announced a significant collaboration with the Wilmot Cancer Institute at the University of Rochester Medical Center (URMC). This partnership aims to enhance the discovery of new patient-centric therapies for cancer treatment. As a leading figure in biotechnological research, Indivumed plans to leverage its extensive expertise in standardized tissue collection and clinical data utilization to expedite the development of innovative cancer therapies.

A Comprehensive Research Resource

Indivumed's innovative platform is built on meticulously collected surgical tissue samples and comprehensive clinical data, which are crucial for advancing cancer research and drug development focused on patient needs. The collaboration will see the URMC contribute its expertise in gathering and processing high-quality biological samples and clinical data, adhering to rigorous operational protocols set forth by Indivumed. One of the key advantages of this partnership is the ability to reduce ischemia time to under ten minutes, thereby ensuring the integrity and quality of each sample collected.

The joint research efforts will prioritize creating well-characterized tumor models derived from these tissue samples. These cellular models, which include classic cell cultures, spheroids, and organoids, complemented by data analytics, will help streamline and de-risk the process of identifying, validating, and screening ligand interactions, as well as developing pharmaceutical molecular targets against cancer.

Dr. Hartmut “Hucky” Land, Deputy Director of the Wilmot Cancer Institute, expressed his enthusiasm for the collaboration, stating, “We have successfully partnered with Indivumed in the past; our familiarity with their tissue and multi-omic data approach provides an excellent foundation for this new project. This endeavor will create further opportunities to identify new therapies and biomarkers, providing insights into target-patient compatibility for clinical decision-making, ultimately advancing cancer care.”

Focus on Advanced Stages of Specific Cancers

Initially, the collaboration will focus on advanced stages of solid tumors with significant unmet medical needs, including colorectal cancer, pancreatic cancer, lung cancer, and breast cancer. There is also potential for expanding research efforts to other cancer types in the future. The knowledge gained through this partnership will advance ongoing research initiatives and the development of Indivumed’s assets, providing valuable guidance to participating clinicians in their therapeutic decision-making processes.

CEO and founder of Indivumed, Hartmut Juhl, commented on the deepened partnership with URMC. He noted, “This significantly strengthens our capacity to identify new cancer therapies within a truly patient-centric approach. We will develop primary tumor models to test new compounds against targets identified through our unique AI-driven data analysis capabilities, aiming to deliver new therapeutics to patients as quickly and accurately as possible.”

As part of this agreement, the University of Rochester Medical Center becomes a member of Indivumed's global clinical network, which already includes numerous renowned hospitals and leading oncology institutes across North America, Europe, and Asia. This collaboration builds upon successful past efforts, which included a recent publication discussing a novel classification method for distinct types of colon cancer.

About the Wilmot Cancer Institute

The Wilmot Cancer Institute at the University of Rochester is an NCI-designated cancer center located in Rochester, New York. It serves a population of over three million people across 27 counties in western and central New York and is recognized as the regional leader in cancer care and research. As a component of the Strong Memorial Hospital, the Wilmot Cancer Institute provides specialized cancer care services at the University of Rochester Medical Center and a network of 13 sites in the area, including an 88-bed hospital on the Medical Center campus. The Wilmot Cancer team comprises over 190 oncologists, more than 500 oncology nurses, and around 115 scientists dedicated to studying various aspects of cancer.

About Indivumed

Indivumed is a biotechnology company specializing in precision oncology. The company is committed to discovering new therapeutic targets for the development of precision cancer treatments, with the aspiration of ensuring that every cancer patient has access to targeted therapeutic options. To achieve this goal, Indivumed dedicates its expertise and insight into cancer research to the identification, validation, and preclinical development of cutting-edge therapeutic products. With over twenty years of experience and a unique resource that is built around a standardized collection process ensuring less than ten minutes of cold ischemia time, Indivumed is dedicated to redefining oncology and bringing the best possible therapies to patients.